Your English writing platform
Discover LudwigExact(11)
Results of a post hoc cohort analysis of the association between antihypertensive treatment and carotid artery intima-media thickness (CIMT) in the Troglitazone Atherosclerosis Regression Trial (TART), a randomized trial designed to evaluate the impact of troglitazone treatment on CIMT progression in adults with insulin-requiring type 2 DM, are reported.
Tissue samples were collected three weeks after treatment in the regression trial.
The Regression Trial started at the age of 12.6 weeks (about 88 days after birth).
In the regression trial the extension of survival time was about 3 weeks (p = 0.001, log-rank).
Thus, a condition of 'stable disease' was achieved in the group that received the combinatorial therapy In the regression trial, RIP1-Tag2 mice with substantial tumor burden and minimal life expectancy were treated beginning at week 13 [ 33].
Rip1-Tag2 mice were given the combination treatment at 10-weeks and again at 13-weeks of age for an intervention trial, or at 13 and 16-weeks for a regression trial.
Similar(49)
Both intervention and regression trials were conducted.
Although radiation treatment alone impaired tumor growth in both intervention and regression trials, it produced no significant extension of survival time in either trial.
In contrast, there was a significant extension of survival of cohorts receiving the combinatorial treatment in the intervention and regression trials.
Because the combination of sub-lethal radiation and TCR splenocyte transfer lead to significant reduction in tumor burden in both intervention and regression trials, we asked whether the radiation had increased the number of tumor-infiltrating lymphocytes.
To evaluate the effects of the various treatments on survival, we performed intervention and regression trials on cohorts of Rip1-Tag2 mine, in which groups received no treatment, radiation alone, or the combinatorial treatment, in which the endpoint was survival.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com